Beijing Leadman Biochemistry Co Ltd - Asset Resilience Ratio
Beijing Leadman Biochemistry Co Ltd (300289) has an Asset Resilience Ratio of 18.19% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Beijing Leadman Biochemistry Co Ltd's Asset Resilience Ratio has changed over time. Check Beijing Leadman Biochemistry Co Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Beijing Leadman Biochemistry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Beijing Leadman Biochemistry Co Ltd (300289) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥320.91 Million | 18.19% |
| Total Liquid Assets | CN¥320.91 Million | 18.19% |
Asset Resilience Insights
- Good Liquidity Position: Beijing Leadman Biochemistry Co Ltd maintains a healthy 18.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Beijing Leadman Biochemistry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Beijing Leadman Biochemistry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Bactiguard Holding AB (publ)
ST:BACTI-B |
Medical Devices | 8.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for Beijing Leadman Biochemistry Co Ltd (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Beijing Leadman Biochemistry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.96% | CN¥336.75 Million ≈ $49.28 Million |
CN¥1.78 Billion ≈ $259.91 Million |
+1.61pp |
| 2024-12-31 | 17.35% | CN¥316.14 Million ≈ $46.26 Million |
CN¥1.82 Billion ≈ $266.68 Million |
+2.37pp |
| 2023-12-31 | 14.98% | CN¥290.29 Million ≈ $42.48 Million |
CN¥1.94 Billion ≈ $283.65 Million |
-- |
About Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnolo… Read more